Skip to main content

Advertisement

Table 3 Effects of the 5-week resistance training program in the PLA and BA groups

From: Effects of β-alanine supplementation during a 5-week strength training program: a randomized, controlled study

Variable Group Pre (mean ± SD ± CI) Post (mean ± SD ± CI) Post-Pre(u) Post-Pre (%) CI (95%) p for Group p for Time p for GroupXTime
Kg at 1RM (kg) PLA 123.92 ± 18.02 (112.38–135.45) 139.33 ± 15.13 (129.45–149.22) 15.41 12.44% 121.16–142.09 0.484 < 0.001* 0.014*
BA 124.57 ± 20.42 (113.89–135.25) 148.50 ± 17.73 (139.35–157.65) 23.93 19.21% 126.85–146.22
AV at 1RM (m·s−1) PLA 0.325 ± 0.073 (0.29–0.36) 0.370 ± 0.125 (0.29–0.45) 0.045 12.16% 0.31–0.39 0.328 0.023* 0.354
BA 0.324 ± 0.049 (0.29–0.36) 0.426 ± 0.137 (0.35–0.50) 0.102 31.57% 0.34–0.41
PV at 1RM (m·s−1) PLA 0.844 ± 0.222 (0.71–0.8) 0.951 ± 0.203 (0.86–1.05) 0.107 12.7% 0.80–1.00 0.802 0.044* 0.626
BA 0.881 ± 0.224 (0.76–1.00) 0.947 ± 0.113 (0.86–1.04) 0.066 7.49% 0.82–1.01
AP at 1RM (W) PLA 392.16 ± 87.69 (342.70–441.63) 474.8 ± 104.58 (409.99–539.61) 82.64 21.07% 384.77–482.19 0.185 < 0.001* 0.056
BA 395.14 ± 78.86 (349.35–440.94) 559.70 ± 112.20 (499.71–619.70) 164.56 41.65% 432.33–522.52
PP at 1RM (W) PLA 1159.5 ± 338.91 (939.31–1379.69) 1467.42 ± 334.48 (1297.52–1637.31) 307.92 26.56% 1136.50–1490.42 0.332 < 0.001* 0.774
BA 1258.79 ± 393.66 (1054.92–1462.64) 1599.64 ± 235.49 (1442.35–1756.94) 300.85 23.89% 1265.38–1593.05
Kg at Pmax (kg) PLA 91.42 ± 15.73 (83.02–99.81) 106.00 ± 12.43 (97.71–114.28) 14.58 15.95% 90.90–106.52 0.896 < 0.001* 0.356
BA 90.29 ± 12.53 (82.51–98.06) 108.50 ± 15.03 (100.83–116.17) 18.21 20.17% 92.16–106.62
AV at Pmax (m·s−1) PLA 0.735 ± 0.096 (0.69–0.78) 0.698 ± 0.072 (0.66–0.74) − 0.037 −5.03% 0.68–0.75 0.861 0.373 0.226
BA 0.710 ± 0.054 (0.67–0.75) 0.716 ± 0.055 (0.68–0.75) 0.006 0.85% 0.68–0.74
PV at Pmax (m·s−1) PLA 1.289 ± 0.122 (1.22–1.36) 1.246 ± 0.088 (1.19–1.30) − 0.043 − 3.34% 1.22–1.32 0.497 0.323 0.354
BA 1.291 ± 0.102 (1.23–1.35) 1.289 ± 0.086 (1.24–1.34) − 0.002 −0.15% 1.25–1.34
AP at Pmax (W) PLA 654.75 ± 113.98 (586.27–723.23) 725.08 ± 106.84 (664.74–785.43) 70.33 10.74% 628.31–751.53 0.904 < 0.001* 0.034*
BA 631.21 ± 115.73 (567.82–694.61) 758.50 ± 96.33 (702.63–814.37) 127.29 20.17% 637.82–751.90
PP at Pmax (W) PLA 1397.25 ± 245.66 (1242.88–1551.62) 1565.75 ± 146.17 (1445.86–1685.63) 168.5 12.06% 1351.76–1611.24 0.494 < 0.001* 0.137
BA 1408.43 ± 269.93 (1265.51–1551.34) 1673.57 ± 238.06 (1562.58–1784.57) 265.14 18.83% 1420.88–1661.12
Mean AV (m·s−1) PLA 0.673 ± 0.046 (0.65–0.70) 0.705 ± 0.058 (0.68–0.73) 0.032 4.75% 0.67–0.71 0.988 < 0.005* 0.905
BA 0.674 ± 0.049 (0.65–0.70) 0.704 ± 0.033 (0.68–0.73) 0.050 5.05% 0.68–0.71
Mean AP (W) PLA 506.73 ± 68.56 (458.34–555.21) 589.07 ± 73.10 (543.27–634.87) 82.34 16.25% 502.80–593.04 0.611 < 0.001* 0.383
BA 514.13 ± 90.68 (469.29–558.97) 612.44 ± 79.92 (570.04–654.84) 98.31 19.12% 521.51–605.06
  1. PLA Placebo, BA β-alanine supplementation, Pmax Maximun power, AP Average power, PP Peak power, AV average velocity, PV Peak velocity, 1RM one-repetition maximun, kg Kilogram, W Watts, m·s−1 m·second, * = Significant difference (p < 0.05). Data expressed as mean ± standard deviation (SD), ± 95% confidence intervals (CI)